These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7586227)

  • 41. Orally administered heparins prevent arterial thrombosis in a rat model.
    Pinel C; Wice SM; Hiebert LM
    Thromb Haemost; 2004 May; 91(5):919-26. PubMed ID: 15116252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose heparin as an antithrombotic agent.
    Gensini GF; Bonechi F; Gori AM; Fortini A; Paniccia R; Lamberti R; Attanasio M; Martini F; Prisco D; Neri Serneri GG
    Haemostasis; 1990; 20 Suppl 1():129-31. PubMed ID: 2083864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix.
    Han D; Liu W; Ao Q; Wang G
    Med Hypotheses; 2008 Sep; 71(3):374-8. PubMed ID: 18565684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms.
    Sho E; Chu J; Sho M; Fernandes B; Judd D; Ganesan P; Kimura H; Dalman RL
    J Vasc Surg; 2004 Jun; 39(6):1312-21. PubMed ID: 15192574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heparin-binding growth factor-I (endothelial cell growth factor) binds to endothelium in vivo.
    Rosengart TK; Kupferschmid JP; Ferrans VJ; Casscells W; Maciag T; Clark RE
    J Vasc Surg; 1988 Feb; 7(2):311-7. PubMed ID: 2448501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mass transport, atherogenesis, and risk.
    Fry DL
    Arteriosclerosis; 1987; 7(1):88-100. PubMed ID: 3813979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and preclinical pharmacokinetics of a novel subcutaneous thermoresponsive system for prolonged delivery of heparin.
    Matanović MR; Grabnar PA; Voinovich D; Golob S; Mijovski MB; Grabnar I
    Int J Pharm; 2015 Dec; 496(2):583-92. PubMed ID: 26529577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of transmural pressure on low density lipoprotein and albumin transport and distribution across the intact arterial wall.
    Curmi PA; Juan L; Tedgui A
    Circ Res; 1990 Jun; 66(6):1692-702. PubMed ID: 1693106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of adenoviral transport mechanisms in the vessel wall and optimization of gene transfer using local delivery catheters.
    Palasis M; Luo Z; Barry JJ; Walsh K
    Hum Gene Ther; 2000 Jan; 11(2):237-46. PubMed ID: 10680838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury.
    Wu B; Mottola G; Chatterjee A; Lance KD; Chen M; Siguenza IO; Desai TA; Conte MS
    J Vasc Surg; 2017 Jan; 65(1):207-217.e3. PubMed ID: 27034112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heparin fails to suppress intimal proliferation in experimental vein grafts.
    Cambria RP; Ivarsson BL; Fallon JT; Abbott WM
    Surgery; 1992 Apr; 111(4):424-9. PubMed ID: 1557688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new approach for local intravascular drug delivery. Iontophoretic balloon.
    Fernández-Ortiz A; Meyer BJ; Mailhac A; Falk E; Badimon L; Fallon JT; Fuster V; Chesebro JH; Badimon JJ
    Circulation; 1994 Apr; 89(4):1518-22. PubMed ID: 8149516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distribution of superparamagnetic Au/Fe nanoparticles in an isolated guinea pig brain with an intact blood brain barrier.
    Sanavio B; Librizzi L; Pennacchio P; Beznoussenko GV; Sousa F; Silva PJ; Mironov AA; Frassoni C; Stellacci F; de Curtis M; Krol S
    Nanoscale; 2018 Dec; 10(47):22420-22428. PubMed ID: 30475372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The heparin target organ--the endothelium. Studies in a rat model.
    Hiebert LM; Wice SM; McDuffie NM; Jaques LB
    Q J Med; 1993 May; 86(5):341-8. PubMed ID: 8327652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose model for stent-based delivery of a radioactive compound for the treatment of restenosis in coronary arteries.
    Janicki C; Hwang CW; Edelman ER
    Med Phys; 2003 Oct; 30(10):2622-8. PubMed ID: 14596298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exercise training alters endothelium-dependent vasoreactivity of rat abdominal aorta.
    Delp MD; McAllister RM; Laughlin MH
    J Appl Physiol (1985); 1993 Sep; 75(3):1354-63. PubMed ID: 8226551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vascular injury by endotoxin: changes in macromolecular transport parameters in rat aortas in vivo.
    Penn MS; Saidel GM; Chisolm GM
    Am J Physiol; 1992 May; 262(5 Pt 2):H1563-71. PubMed ID: 1590461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liphophilic complexation of heparin based on bile acid for oral delivery.
    Lee DY; Lee J; Lee S; Kim SK; Byun Y
    J Control Release; 2007 Oct; 123(1):39-45. PubMed ID: 17765350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis.
    Edelman ER; Karnovsky MJ
    Circulation; 1994 Feb; 89(2):770-6. PubMed ID: 8313565
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombogenicity of the injured vessel wall--role of antithrombin and heparin.
    Frebelius S; Hedin U; Swedenborg J
    Thromb Haemost; 1994 Jan; 71(1):147-53. PubMed ID: 8165634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.